Bruker (BRKR) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Bruker

NasdaqGS•Healthcare•Medical Devices

$53.43-0.13(<0.01%)Market closed

Market Cap

$9.60B

P/S

2.7x

P/B

4.0x

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.

How this company scores

AverageMetricSide Score: 54/100

Strongest: Cash & Earnings Quality (22/25); weakest: Growth (8/25).

Profitability8/25

Growth8/25

Balance Sheet & Red Flags16/25

Cash & Earnings Quality22/25

Strengths

Rising free cash flowLong cash runwayCash-backed earningsImproving leverage

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 78.5x5y range 0.0x – 78.5x

Currently above its 16-quarter median.

P/S · 2.7x5y range 0.0x – 5.1x

Currently above its 20-quarter median.

P/B · 4.0x5y range 0.0x – 11.1x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 123.0% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Cash Burn

Watch

FCF turned negative in 3 of the last 8 quarters — occasional cash consumption.

Price & Volume

Market Cap $9.60B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $3.50B
Q. Revenue: $838.50M
TTM EBITDA: $199.50M
TTM Op. Income: $-30.60M
Q. Op. Income: $-65.30M
TTM Net Income: $-71.20M
Q. Net Income: $-52.00M
EPS: $-0.41
Shares Out.: $152.30M

$3.50B in TTM revenue grew 1.6% YoY, reaching $838.50M last quarter. TTM EBITDA of $199.50M and TTM operating income of $-30.60M show growth is flowing through to the bottom line. However, net income is negative at $71.20M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 2 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 49.6%
EBITDA Margin: -0.9%
Op. Margin: -7.8%
Net Margin: -6.2%

Op. margin of -7.8% is down 9.3% YoY — costs are rising relative to revenue. Net margin at -6.2% and gross margin of 49.6% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 2.7x
P/B Ratio: 4.0x

P/S of 2.7x and P/B of 4.0x. Across the last 4 quarters, P/E has risen for 3 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $6.05B
Cash: $184.90M
Long-Term Debt: $1.81B
Book Value: $2.40B
D/E Ratio: 0.8
Debt/EBITDA: N/A

With $6.05B in assets and $1.81B in long-term debt, D/E is 0.8and book value is $2.40B — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is down 42% — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-77.40M
TTM Free Cash Flow: $93.90M
FCF Margin: 2.7%
FCF / Net Income: -1.3

TTM FCF of $93.90M on $-77.40M in operating cash flow. The FCF / Net Income ratio of -1.3x means the business consumes cash — it is not yet self-funding. Across the last 8 quarters, free cash flow has risen for 3 consecutive quarters — an improving trend.